Gilead are buying alot of things.
I have it on good authority they are exploring very adventurous options with many reasons to be optomistic.
It caught my eye as well. Anyway, today is the day for Arrowhead and other bio-tech companies in HBV space to present at Jefereies conference. I hope we can get good updates from it.
It is interesting that Gilead's VP said they have moved their entire HCV team to HBV. But then their HCV team did not really discover the cure for HCV, they bought it. Not giving away much about what they are working on for HBV and whether there are any HBV takeover targets.
Just my personal opinion.